There are two main types of cholinergic receptors widely distributed throughout in the brain. These receptors are classified as muscarinic and nicotinic receptors. In certain regions of the brain only the muscarinic subtype is found eg midbrain, medulla, and pons while in other regions eg substantia nigra, locus coeruleus and septum only the nicotinic receptor subtype is found. Both sub-types are located in the corpus striatum, cerebral cortex, hippocampus, thalamus, hypothalamus and cerebellum.
There are two main types of cholinergic receptors widely distributed throughout in the brain; the muscarinic and nicotinic receptors. In certain regions of the brain (eg midbrain, medulla, and pons) only the muscarinic subtype is found while in other regions (eg substantia nigra, locus coeruleus and septum) only the nicotinic receptor subtype is found. Both subtypes are colocalised in the corpus striatum, cerebral cortex, hippocampus, thalamus, hypothalamus and cerebellum. Alzheimer’s disease is associated with a reduction of all cholinergic neurones in the subcortical areas of the brain, leading to reduced availability of acetylcholine.
There are two main types of cholinergic receptors in the brain, muscarinic and nicotinic receptors. Muscarinic receptors are further classified as M1–M5, and nicotinic as NN and NM. The muscarinic receptors are widely distributed throughout the central nervous system. Briefly, these receptors can be found in the cerebral cortex, corpus striatum, limbic system, thalamus, hypothalamus, midbrain and brainstem.
The nicotinic acetylcholine receptor is one of the main mediators of neurotransmission. This receptor is activated by the binding of two acetylcholine molecules. It is a ligand gated ion channel, which permits the movement of positively charged ions out of the synaptic cleft. The receptor is composed of five sub-units – two alpha, one beta, one gamma and one delta sub-unit.
There are two main types of cholinergic receptors in the brain, muscarinic and nicotinic receptors. Muscarinic receptors are further classified as M1–M5 receptors, and nicotinic as NN and NM receptors. The muscarinic receptors are widely distributed throughout the central nervous system. Briefly, these receptors can be found in the cerebral cortex, corpus striatum, limbic system, thalamus, hypothalamus, midbrain and brainstem. There is evidence to suggest that there is increased expression of cholinergic receptors in the brains of depressed people. Anticholinergic compounds are also reported to be mood elevating.
There are two main types of cholinergic receptors – muscarinic and nicotinic acetylcholine receptors. The muscarinic receptors are further classified into M1–M5 receptors. The receptors are distinguished by location, post-receptor signalling pathway and agonist or antagonist interaction. The M1 receptor is the most significant receptor in the central nervous system and is highly expressed in the brain and nerves. Recently, muscarinic M1 receptor agonists have become the focus of research into the treatment of Alzheimer’s disease. M1 agonists may increase acetylcholine transmission in the brain and alleviate some of the symptoms of Alzheimer’s disease.
Acetylcholine (Ach) is synthesised from acetyl-coA and choline in the cytoplasm of autonomic nerve terminals. The final step in the synthesis is catalysed by the enzyme choline acetyltransferase (CAT). Once formed, Ach is transported into and packaged into synaptic vesicles. Moderately potent inhibitors of CAT do exist but they have no therapeutic benefit and this is due in part to the uptake of choline being the rate-limiting step in the synthesis of Ach.
Acetylcholine (Ach) is synthesised from acetyl-coA and choline in the cytoplasm of autonomic nerve terminals. The final step in the synthesis is catalysed by the enzyme choline acetyltransferase (CAT). In Alzheimer’s disease CAT is less active than in an non-Alzheimer’s brain resulting in a reduction in the synthesis of Ach. As CAT activity declines, less ACH is packaged into the synaptic vesicles and released at the nerve terminal. This deficit in Ach leads to decreased neurotransmission and is implicated in the pathogenesis of Alzheimer’s disease
Cholinergic nerve transmission is terminated by the enzyme acetylcholinesterase (AchE). AchE is found both on the post-synaptic membrane of cholinergic synapses and in other tissues eg red blood cells. Acetylcholine (Ach) binds to AchE and is hydrolysed to acetate and choline. This inactivates the Ach and the nerve impulse is halted. AchE inhibitors (eg rivastigmine) prevent the hydrolysis of Ach, which increases the concentration of Ach in the synaptic cleft; AchE inhibitors are widely used in the treatment of Alzheimer’s disease.
There are two different types of acetylcholine receptor – the nicotinic and muscarinic receptors. The muscarinic receptors are further classified into M1–M5 subtypes. The M1 receptors are widely distributed throughout the neurones of the central nervous system. Coupled to stimulatory G-proteins, M1 muscarinic acetylcholine receptors have a stimulatory effect on neurotransmission when bound by an agonist. M3 and M5 receptor subtypes also have a stimulatory effect on the target tissue, whereas the M2 and M4 subtypes are inhibitory.
The acetylcholine muscarinic M1 receptor is the most abundant sub-type of the acetylcholine receptor in the brain. When an agonist, such as acetylcholine, binds to this receptor a series of down-stream signaling mechanisms or secondary messengers are initiated. This results in the opening of potassium channels and the propagation of a nerve impulse.
The nicotinic acetylcholine receptor is one of the main mediators of neurotransmission. This receptor is activated by the binding of two acetylcholine molecules. It is a ligand gated ion channel, which permits the movement of positively charged ions out of the synaptic cleft. The receptor is composed of five sub-units – two alpha, one beta, one gamma and one delta sub-unit.
The nicotinic acetylcholine receptor is one of the main mediators of neurotransmission. This receptor is activated by the binding of two acetylcholine molecules. As a ligand gated ion channel it permits the movement of positively charged ions from the synaptic cleft into the cytoplasm.